Background Osteoporosis is a metabolic bone disorder that leads to low bone mass and microstructural deterioration of bone tissue and increases bone fractures. Resveratrol, a natural polyphenol compound, has pleiotropic effects including anti-oxidative, anti-aging, and anti-cancer effects. Resveratrol also has roles in increasing osteogenesis and in upregulating mitochondrial biogenesis of bone-marrow derived mesenchymal stem cells (BM-MSCs). However, it is still unclear that resveratrol can enhance osteogenic differentiation or mitochondrial biogenesis of periosteum-derived MSCs (PO-MSCs), which play key roles in bone tissue maintenance and fracture healing. Thus, in order to test a possible preventive or therapeutic effect of resveratrol on osteoporosis, this study investigated effects of resveratrol treatments on osteogenic differentiation and mitochondrial biogenesis of PO-MSCs. Methods The optimal doses of resveratrol treatment on PO-MSCs were determined by cell proliferation and viability assays. Osteogenic differentiation of PO-MSCs under resveratrol treatment was assessed by alkaline phosphatase activities (an early biomarker of osteogenesis) as well as by extracellular calcium deposit levels (a late biomarker). Mitochondrial biogenesis during osteogenic differentiation of PO-MSCs was measured by quantifying both mitochondrial mass and mitochondrial DNA (mtDNA) contents. Results Resveratrol treatments above 10 µM seems to have negative effects on cell proliferation and viability of PO-MSCs. Resveratrol treatment (at 5 µM) on PO-MSCs during osteogenic differentiation increased both ALP activities and calcium deposits compared to untreated control groups, demonstrating an enhancing effect of resveratrol on osteogenesis. In addition, resveratrol treatment (at 5 µM) during osteogenic differnetiation of PO-MSCs increased both mitochondrial mass and mtDNA copy numbers, indicating that resveratrol can bolster mitochondrial biogenesis in the process of PO-MSC
osteogenic differentiation.
Conclusion Taken together, this study describes roles of resveratrol in promoting osteogenesis and mitochondrial biogenesis of human PO-MSCs suggesting a possible application of resveratrol as a supplement for osteoporosis and/or osteoporotic fractures.
Background
Elderly people occupy the fastest growing segment of populations throughout the world. Accordingly, the age-associated bone diseases such as osteoporosis have been increasing.
Due to low mineral density and concomitant change of microarchitecture of the bone tissue, osteoporosis manifests as an increased risk of bone fracture (1). The life time risk for an osteoporotic hip, spine, or forearm fracture at the age of 50 years has been estimated to be 40 ~ 53% in women and 13 ~ 22% in men (2) . These osteoporotic fractures are not only problematic in the fracture itself, but they also exacerbate the patient's medical condition, affect mortality, and increase socioeconomic costs (3, 4) . Therefore, many attempts aimed at diagnosis and treatment for osteoporosis have been conducted to prevent osteoporotic fracture.
Adult mesenchymal stem cells (MSCs) are multipotent stem cells capable of differentiating into various cell types including adipocyte, chondrocyte and osteocyte (5) .
In addition, adult MSCs have some benefits regarding immunologic and ethnic issues relative to embryonic stem cells. Thus, MSCs have been actively applied as a material for regenerative medicine for osteoporosis treatment (6) (7) (8) . Traditionally, bone marrowderived MSCs (BM-MSCs) have been widely chosen as a stem cell source in regenerative medicine (9) . However, BM-MSCs also have some limitations. For example, BM-MSC isolation needs bone marrow aspiration which is painful and has a risk of infection.
Furthermore, BM-MSCs from older bone marrow were reported to have decreased expansion and differentiation potentials (10, 11) . Unfortunately, there is a report that BM-MSCs do not make much contribution to fracture healing (12) . Besides the bone marrow, the periosteum also contains adult MSCs. These periosteum-derived MSCs (PO-MSCs) are known to play an important role in fracture healing (12) . Moreover, PO-MSCs seem to maintain their differentiation potentials even with increasing age (13, 14) . These advantages make PO-MSCs an attractive MSC source in regenerative medicine for the bone (15) .
Recently, metabolic shift from glycolysis to mitochondrial oxidative phosphorylation (OXPHOS) is taking on increased importance in stem cell differentiation (16, 17) .
Glycolytic metabolism is known as the main metabolism for self-renewal and maintenance in proliferating stem cells. However, when stem cells commit to differentiate, glycolytic metabolism is shifted to mitochondrial OXPHOS to meet an increased cellular energy demand in differentiated cells (18, 19) . OXPHOS occurs within mitochondria where the mitochondrial respiratory complexes and the ATP synthase produce ATP. Catalytic core subunits of mitochondrial respiratory complexes as well as the ATP synthase are encoded in mitochondrial DNA (mtDNA). Thus, if cells require more ATP during stem cell differentiation, cells need to up-regulate mitochondrial biogenesis leading to an increased cellular mitochondrial mass and mtDNA contents.
Resveratrol is a natural polyphenol found in red grapes, peanuts, berries, and pomegranates etc (20, 21). Resveratrol has pleiotropic effects including anti-oxidative, anti-aging, and anti-cancer effects (22) (23) (24) (25) . Among these diverse effects of resveratrol, one notable benefit of resveratrol is to increase mitochondrial biogenesis in mammalian cells (26, 27) . Moreover, resveratrol also promotes osteogenic differentiation of bone marrow or adipose tissue derived mesenchymal stem cells (28, 29) . However, so far, it is still unclear that resveratrol can enhance osteogenic differentiation or mitochondrial biogenesis of PO-MSCs which play important roles in bone fracture healing. Thus, this 5 study investigated whether resveratrol has a role in osteogenic differentiation and mitochondrial biogenesis of PO-MSCs.
Materials And Methods

Reagents, in vitro cell cultures, and osteogenesis of human periosteum-derived mesenchymal stem cells (PO-MSCs)
All chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell culture media and fetal bovine serum were purchased from Invitrogen (Waltham, MA, USA). Human periosteal tissues were obtained from patients who granted informed consent for collection of the tissues, as required by the Ethics Committee of Gyeongsang National University Hospital (GNUH 2014-05-012). PO-MSCs were then isolated as described previously (19) . Briefly, periosteal explants were harvested from mandibles during surgical extraction of impacted lower third molars. Periosteal pieces were washed and cultured at 37°C, 95% humidified air, and 5% CO 2 in 100-mm culture dishes containing Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% heatinactivated fetal bovine serum, 100 IU/mL penicillin, and 100 μg/mL streptomycin.
Resulting adherent cells were passaged by gentle trypsinization and reseeding in a fresh medium. The cell culture medium was changed every 3 days during the isolation period.
For osteogenic differentiation, PO-MSCs were cultured using osteogenesis induction medium (OM) which is composed of DMEM, supplemented with 50 μg/mL L-ascorbic acid 2phosphate, 10 nM dexamethasone, and 10 mM β-glycerophosphate (19) .
Assessment of PO-MSC proliferation and viability under resveratrol treatments
Proliferation of PO-MSCs was measured by a cell counting. Briefly, 2 × 10 4 cells were seeded in 24-well plates and were cultured in OM medium. Resveratrol treatment was 6 performed by treating cells with vehicle (ethanol) or a range of resveratrol concentrations from 500 nM upto 20 µM. 5 day and 10 day cultures were trypsinized and resulting detached cells were counted with a hemocytomer. Viability of PO-MSCs treated with resveratrol was determined by MTT assays. Shortly, 2 × 10 4 cells were seeded in 24-well plates and cultured in OM medium with resveratrol treatments (500 nM ~ 20 µM). 5 day and 10 day cultures were subjected to a colorimetric MTT assay.
Measurements of alkaline phosphatase (ALP) activities
ALP activities were determined colorimetrically using an ALP Assay Kit (Takara, Kusatsu, Japan) according to the manufacturer's instructions. In brief, whole cell lysates were prepared using a NP-40 lysis buffer (Thermo Scientific, Waltham, USA). Cell lysates were then incubated with p-nitrophenylphosphate, a colorless substrate for ALP, in a Tris-HCl buffer (pH 9.5) at 37 ℃ for 15 min. Upon splitting off the phosphate group of pnitrophenylphosphate by ALP, p-nitrophenol is released and detected spectrophotometrically (absorption maximum, 405 nm). These ALP activities then were normalized to cellular protein contents determined by the Bradford method.
Measurements of calcium deposits
Mineralization of PO-MSC cultures with resveratrol treatments (500 nM and 5 µM) in OM medium was assessed by von Kossa staining [30] . Calcium contents during osteogenesis of PO-MSCs were also measured by a calcium deposition assay. In brief, at days 14 and 21 of cell cultures, PO-MSCs grown in OM medium with resveratrol treatments (500 nM and 5 µM) were decalcified with 0.6-N HCl for 1 day at room temperature. Then, the calcium content was determined by the colorimetrical o-cresolphthalein complexone method (Calcium C-test, Wako Chemicals, Japan), whereby calcium reacts with o-cresolphthalein to form a purple complex that absorbs light with wavelength of 570 nm. After decalcification, the total protein content in the supernatants was measured by the Bradford method and was used to normalize calcium content. 
mtDNA copy number analysis by quantitative PCR
For mtDNA copy number analysis, total cellular DNA was extracted from cultured PO-MSCs.
A quantitative real-time PCR method was used to determine the relative abundance of mtDNA versus nuclear 18S rDNA using corresponding mitochondrial and nuclear PCR primer sets in two parallel PCR reactions as described previously (19) . Relative mtDNA copy number was calculated as the ratio of the amount of amplification obtained with mtDNA versus nuclear 18S rDNA PCR primer sets for each sample and plotted normalized to the control group. The sequence of the PCR primer pairs are as follows: the nuclear 18S rRNA fragment was amplified by the primer pair 5'-TAGAGGGACAAGTGGCGTTC-3' and 5'-8 CGCTGAGCCAGTCAGTGT-3'; and the mitochondrial COX1 fragment was amplified by the primer pair 5'-CACCCAAGAACAGGG TTTGT-3-3' and 5 '-TGGCCATGGGTATGTTGTTAA-3'.
Statistical analysis
All experiments were performed using at least three independent cell cultures. Error bars in all figures represent the mean ± SEM and statistical analyses were computed using Graphpad Prism 7 software (GraphPad, San Diego, CA, USA). The Student's two-tailed ttest was used for the determination of statistical relevance between groups, and a p value of <0.05 was considered statistically significant.
Results
Resveratrol treatments does not affect neither PO-MSC proliferation nor its viability.
In order to see effects of resveratrol on cell proliferation and viability during osteogenesis, PO-MSCs were cultured in OM medium for 5 and 10 days. For the same periods of cultures, these PO-MSCs were also treated with various concentrations of resveratrol from 500 nM upto 20 µM. At day 5 and day 10 cultures, cells were harvested and counted with a hemocytometer for cell proliferation or were subjected to an MTT assay for cell viability. condition. This mineralization is further increased by resveratrol treatments (500 nM and 5 µM) in time-and dose-dependent manners relative to untreated OM condition. In addition, colorimentric quantitation assays for calcium contents in cell cultures showed that calcium contents in PO-MSCs were increased by OM condition relative to DMEM 10 condition, and this increase were further enhanced by resveratrol treatments (Fig. 3B ).
Together, these results demonstrate that 500 nM and 5 µM resveratrol treatments can enhance matrix mineralization during osteogenic differentiation of PO-MSCs. resveratrol increased mitochondrial mass in a dose-dependent manner (Fig. 4B ).
Furthermore, mtDNA contents measured by qPCR were also increased by resveratrol treatments in osteogenically differentiated PO-MSCs relative to controls (Fig. 4C ).
Together, these findings clearly showed that mitochondrial biogenesis can be up-regulated by resveratrol during the osteogenic differentiation of PO-MSCs.
Discussion
In this study, we demonstrated that resveratrol treatments (5 µM) up-regulate both ALP activities and calcium deposits during osteogenic differentiation of PO-MSCs compared to the untreated controls. These results indicate that resveratrol can enhance osteogenic differentiation of PO-MSCs. In other studies, resveratrol was reported to promote osteogenic differentiation of bone marrow or adipose tissue derived MSCs at higher concentrations (28) (29) (30) (31) (32) . However, in this study, PO-MSC viability decreased when resveratrol dose was above 10 µM. It seems that the osteogenic effect of resveratrol varies according to dosage or cell types (33) (34) (35) (36) (37) . Therefore, further investigation on the optimal dosage and administration method of resveratrol for accelerating osteogenesis of PO-MSC is needed.
In addition, this study showed that resveratrol treatments increase both mitochondrial mass and mtDNA contents during osteogenic differentiation in PO-MSCs. These findings indicate that resveratrol can up-regulate mitochondrial biogenesis during osteogenic differentiation of PO-MSCs and are consistent with other reports regarding mitochondrial biogenesis by resveratrol in various cell types (26, (38) (39) (40) (41) (42) . Moreover, the up-regulation of mitochondrial biogenesis by resveratrol in PO-MSCs is in line with the notion that metabolic shift from glycolysis to mitochondrial OXPHOS occurs during stem cell differentiation (16, 17, (43) (44) (45) (46) (47) . Thus, these results suggest that a small molecule upregulating mitochondrial biogenesis such as resveratrol can be a new modulator that may enhance osteogenesis in adult PO-MSCs for regenerative medicine.
Currently, the most widely used therapeutic agents for osteoporosis are anti-resorptive drugs such as bisphosphonate and selective estrogen receptor modulators (SERMs) (48) .
However, these medications can cause complications when used for a long time. In particular, bisphosphonate has complications such as gastrointestinal irritation, atypical fracture due to decreased bone replacement rate, and osteonecrosis of jaw bone (49) (50) (51) (52) .
In addition, venous thromboembolism can occur as a complication when using SERMs (53, 54) . On the other hand, a bone anabolic agent, teriparatide (a parathyroid hormone analog) has recently been used for osteoporosis treatment. But its disadvantages are the high cost, the need for injection, and the possibility of developing malignant tumors over a long period of time (55) . Thus, there is an increasing demand for a new bone anabolic agent. Interestingly, recent studies have shown that oral intake of adequate amounts of resveratrol can prevent bone fractures (56, 57) . In this regard, this study suggests that resveratrol supplements may be clinically meaningful in increasing bone tissue formation in osteoporotic bones.
Regenerative medicine utilizing adult stem cells has been spotlighted in the prevention and treatment of osteoporosis and osteoporotic fracture (6-8, 58, 59) . However, BM-MSCs have some disadvantages, for example, a decreased cellular expansion and differentiation potentials from older bone marrow tissues. These limitations hinder BM-MSCs from their therapeutic application (10) (11) (12) . Alternatively, PO-MSCs derived from the periosteum of the bone have some benefits. Because they locate in the periosteum, it is expected that they are easy to participate in bone tissue maintenance in vivo. Moreover, the expansion and differentiation potentials of PO-MSCs are maintained even in older ages (13, 14) .
Thus, PO-MSCs were expected to play a more critical role in bone healing than BM-MSCs 
